Cargando…
P548: PRELIMINARY RESULTS OF A PHASE 1, FIRST-IN-HUMAN STUDY OF INA03, AN ANTI-CD71 ANTIBODY-DRUG CONJUGATE IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE LEUKEMIAS
Autores principales: | Garciaz, Sylvain, Bories, Pierre, Lopez Almeida, Leonor, Boher, Jean-Marie, Belanger, Coralie, Recher, Christian, Hermine, Olivier, Vey, Norbert, Launay, Pierre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429269/ http://dx.doi.org/10.1097/01.HS9.0000969100.45170.e9 |
Ejemplares similares
-
miR-1279, miR-548j, miR-548m, and miR-548d-5p Binding Sites in CDSs of Paralogous and Orthologous PTPN12, MSH6, and ZEB1 Genes
por: Ivashchenko, Anatoliy T., et al.
Publicado: (2013) -
miR-548d-3p inhibits osteosarcoma by downregulating KRAS
por: Chen, Jianhua, et al.
Publicado: (2019) -
miR548ai antagonism attenuates exosome-induced endothelial cell dysfunction
por: Xie, Xiujie, et al.
Publicado: (2021) -
miR-548j-5p regulates angiogenesis in peripheral artery disease
por: Lee, Chiu-Yang, et al.
Publicado: (2022) -
Targeting regulated cell death pathways in acute myeloid leukemia
por: Garciaz, Sylvain, et al.
Publicado: (2023)